SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Jung Cassie (Last) (First) (Middle) C/O AQUESTIVE THERAPEUTICS, INC. 30 TECHNOLOGY DRIVE (Street) WARREN NJ 07059 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/01/2023	3. Issuer Name and Ticker or Trading Symbol Aquestive Therapeutics, Inc. [ AQST ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) SVP, Operations	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	36,747(1)(2)	D
Common Stock	2,000	I	By spouse
Common Stock	44	I	By spouse IRA

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	(3)	08/09/2029	Common Stock	25,000	$3.84	D
Non-Qualified Stock Option (right to buy)	(4)	05/12/2030	Common Stock	21,000	$5.69	D
Non-Qualified Stock Option (right to buy)	(5)	06/10/2031	Common Stock	18,750	$4.07	D
Non-Qualified Stock Option (right to buy)	(6)	08/05/2032	Common Stock	25,000	$0.88	D

Explanation of Responses:

1. Includes 4,567 shares acquired pursuant to the Company's employee stock purchase plan.

2. Includes 15,000 restricted stock units ("RSUs"), which are scheduled to vest as follows: 3,750 on March 10, 2023, 3,750 on March 10, 2024 and 7,500 on March 10, 2025.

3. Grant of non-qualified stock options, of which 25% vested on August 9, 2020, 25% vested on August 9, 2021, and 50% vested on August 9, 2022.

4. Grant of non-qualified stock options, of which 25% vested on May 12, 2021, 25% vested on May 12, 2022, and 50% are scheduled to vest on May 12, 2023.

5. Grant of non-qualified stock options, of which 25% vested on June 10, 2022, 25% are scheduled to vest on June 10, 2023, and 50% are scheduled to vest on June 10, 2024.

6. Grant of non-qualified stock options, which are scheduled to vest as follows: 25% on August 5, 2023, 25% on August 5, 2024, and 50% on August 5, 2025.

Remarks:

Exhibit List Exhibit 24 -- Power of Attorney

	/s/ Lori Braender, as Attorney-In-Fact	01/11/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.